SCHEMBL6474766

SCHEMBL6474766

COc1ccc(-c2cccc(COCCc3cccc(NC(N)=O)c3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 2/20 0.48
ADORA3 P0DMS8 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
MGLL Q99685 1/20 0.44
NLRP3 Q96P20 1/20 0.43
FFAR1 O14842 1/20 0.43
PPARD Q03181 1/20 0.43
AKR1C3 P42330 2/20 0.43
NR3C2 P08235 2/20 0.43
NR1H4 Q96RI1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474650 0.79 PDE4D (0.45) KMT2ASMN1; SMN2POLBMGLLNR3C2
SCHEMBL6479426 0.78 KDM1A (0.43) SENP1FFAR1PPARD
SCHEMBL6477614 0.76 FFAR1 (0.47) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL13596189 0.74 NLRP3 (0.46) NPC1KMT2ASMN1; SMN2NLRP3FFAR1
SCHEMBL13072319 0.72 MDH1 (0.51) MEN1KMT2ASMN1; SMN2CYP3A4NR1H4
SCHEMBL8642110 0.72 CNR1 (0.64) ADORA3MEN1NPC1RAB9AKMT2A
SCHEMBL6474786 0.72 LTB4R (0.41)
SCHEMBL13076917 0.72 NR1H4 (0.45) NPC1RAB9ASMN1; SMN2NR1H4
SCHEMBL12845568 0.70 KIF11 (0.65) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL31688954 0.70 FFAR1 (0.63) NPC1RAB9ASMN1; SMN2FFAR1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 SENP1 3843/4885ADORA3 1495/4885MEN1 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.